Physicochemical properties affecting retinal drug/coumarin-6 delivery from nanocarrier systems via eyedrop administration.
暂无分享,去创建一个
Takuya Fujisawa | Kazuhiro Tsuruma | Masamitsu Shimazawa | Hideaki Hara | Hirofumi Takeuchi | H. Takeuchi | H. Hara | M. Shimazawa | K. Tsuruma | Yuta Inokuchi | Y. Tozuka | Yuichi Tozuka | Kohei Hironaka | T. Fujisawa | Y. Inokuchi | Kohei Hironaka | Yuta Inokuchi
[1] H. Takeuchi,et al. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[2] Ashim K. Mitra,et al. Recent Perspectives in Ocular Drug Delivery , 2009, Pharmaceutical Research.
[3] C. Styles,et al. FIRST VERSUS SECOND EYE INTRAVITREAL RANIBIZUMAB THERAPY FOR WET AMD , 2009, Retina.
[4] R. Soares,et al. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. , 2009, Experimental eye research.
[5] P. Vavia,et al. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[6] Esther S. Kim,et al. Human Scleral Diffusion of Anticancer Drugs from Solution and Nanoparticle Formulation , 2009, Pharmaceutical Research.
[7] K. Csaky,et al. Investigating the Movement of Intravitreal Human Serum Albumin Nanoparticles in the Vitreous and Retina , 2009, Pharmaceutical Research.
[8] A. Badawi,et al. Chitosan based nanocarriers for indomethacin ocular delivery , 2008, Archives of pharmacal research.
[9] G. Abdelbary,et al. Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery , 2008, AAPS PharmSciTech.
[10] G. Noronha,et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. , 2008, The Journal of clinical investigation.
[11] Y. Kawashima,et al. A novel method for measuring rigidity of submicron-size liposomes with atomic force microscopy. , 2008, International journal of pharmaceutics.
[12] S. Krishnakumar,et al. Nanotechnology in ocular drug delivery. , 2008, Drug discovery today.
[13] U. Kompella,et al. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration , 2008, Molecular vision.
[14] M. Ghorab,et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. , 2007, International journal of pharmaceutics.
[15] A. Mitra,et al. Novel approaches to retinal drug delivery , 2007, Expert opinion on drug delivery.
[16] Hiroshi Murata,et al. Involvement of ER stress in retinal cell death , 2007, Molecular vision.
[17] Rania M. Hathout,et al. Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies , 2007, AAPS PharmSciTech.
[18] Clive G. Wilson,et al. Topical and systemic drug delivery to the posterior segments. , 2005, Advanced drug delivery reviews.
[19] U. Kompella,et al. Size‐dependent disposition of nanoparticles and microparticles following subconjunctival administration , 2005, The Journal of pharmacy and pharmacology.
[20] M. Gremião,et al. Colloidal carriers for ophthalmic drug delivery. , 2005, Current drug targets.
[21] J. Irache,et al. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[22] D. Aggarwal,et al. Vesicular systems in ocular drug delivery: an overview. , 2004, International journal of pharmaceutics.
[23] Daniel F. Martin,et al. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. , 2003, American journal of ophthalmology.
[24] M. Iliev,et al. In vivo pachymetry in normal eyes of rats, mice and rabbits with the optical low coherence reflectometer , 2003, Vision Research.
[25] T. Vandamme. Microemulsions as ocular drug delivery systems: recent developments and future challenges , 2002, Progress in Retinal and Eye Research.
[26] F. Nielloud,et al. Emulsions in Health Care Applications—An Overview , 2002 .
[27] D. Maurice,et al. Review: practical issues in intravitreal drug delivery. , 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[28] C. Chiang,et al. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[29] J. Lim,et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. , 1999, American journal of ophthalmology.
[30] M. Alonso,et al. Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers , 1996, The Journal of pharmacy and pharmacology.
[31] H. Utsumi,et al. Motional state of spin-labeled stearates in lecithin-cholesterol liposomes and their incorporation capability. , 1976, Chemical & pharmaceutical bulletin.
[32] U. Kompella,et al. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. , 2008, Investigative ophthalmology & visual science.
[33] S. Benita,et al. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. , 1994, Journal of ocular pharmacology.